Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Shares Outstanding (Weighted Average) (2016 - 2025)

IGC Pharma has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $86.8 million for Q3 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 16.59% to $86.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $86.8 million through Sep 2025, up 16.59% year-over-year, with the annual reading at $76.5 million for FY2025, 30.04% up from the prior year.
  • Shares Outstanding (Weighted Average) was $86.8 million for Q3 2025 at IGC Pharma, up from $83.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $86.8 million in Q3 2025 and troughed at $42.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $53.1 million (2023), against an average of $60.1 million.
  • Year-over-year, Shares Outstanding (Weighted Average) increased 2.83% in 2023 and then soared 37.18% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $49.6 million in 2021, then increased by 5.58% to $52.4 million in 2022, then increased by 8.83% to $57.0 million in 2023, then surged by 36.11% to $77.6 million in 2024, then grew by 11.76% to $86.8 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Shares Outstanding (Weighted Average) are $86.8 million (Q3 2025), $83.0 million (Q2 2025), and $76.5 million (Q1 2025).